Modeling Preventative Strategies against Human Papillomavirus-Related Disease in Developed Countries
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Over the last five years, prophylactic vaccination against Human Papillomavirus (HPV) in pre-adolescent females has been introduced in most developed countries, supported by modeled evaluations which have almost universally found vaccination of pre-adolescent females to be cost-effective. Studies to date suggest that vaccination of pre-adolescent males may also be cost-effective at a cost per vaccinated individual ~US$400–500 if vaccination coverage in females cannot be increased above ~50%; but if it is possible, increasing coverage in females appears to be a better return on investment. Comparative evaluation of the quadrivalent (HPV16,18,6,11) and bivalent (HPV16,18) vaccines centers around the potential tradeoff between protection against anogenital warts and vaccine-specific levels of cross-protection against infections not targeted by the vaccines. Future evaluations will also need to consider the cost-effectiveness of a next generation nonavalent vaccine designed to protect against ~90% of cervical cancers. The timing of the effect of vaccination on cervical screening programs will be country-specific and will depend on vaccination catch-up age range and coverage and the age at which screening starts. Initial evaluations suggest that if screening remains unchanged it will be less cost-effective in vaccinated compared to unvaccinated women but, in the context of current vaccines, will remain an important prevention method. Comprehensive evaluation of new approaches to screening will need to consider the population-level effects of vaccination over time. New screening strategies of particular interest include delaying the start age of screening, increasing the screening interval and switching to primary HPV screening. Future evaluations of screening will also need to focus on the effects of disparities in screening and vaccination uptake, the potential effects of vaccination on screening participation, and the effects of imperfect compliance with screening recommendations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
de Sanjose, S., Quint, W. G., Alemany, L., Geraets, D. T., Klaustermeier, J. E., Lloveras, B., Tous, S., Felix, A., Bravo, L. E., Shin, H.-R., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70230-8 · Cited by 2,728
Paavonen, J., Naud, P., Salmerón, J., Wheeler, C., Chow, S.-N., Apter, D., Kitchener, H., Castellsague, X., Teixeira, J., Skinner, Sr., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61248-4 · Cited by 1,655
Screening for cervical cancer: U.S. preventive services Task force recommendation statement
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-12-201206190-00424 · Cited by 1,049
Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes
Garnett, G. P., Kim, J. J., French, K., & Goldie, S. J. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.05.116 · Cited by 162
Self-citationKulasingam, S. L., Pagliusi, S., & Myers, E. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.09.035 · Cited by 39
Self-citation
Cited by
Bruni, L., Diaz, M., Barrionuevo-Rosas, L., Herrero, R., Bray, F., Bosch, F. X., de Sanjosé, S., & Castellsagué, X. (2016) · The Lancet Global Health · doi:10.1016/s2214-109x(16)30099-7 · Cited by 824
Self-citationComprehensive Control of Human Papillomavirus Infections and Related Diseases
Bosch, F. X., Broker, T. R., Forman, D., Moscicki, A.-B., Gillison, M. L., Doorbar, J., Stern, P. L., Stanley, M., Arbyn, M., Poljak, M., et al. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.07.026 · Cited by 433
Self-citationComprehensive Control of Human Papillomavirus Infections and Related Diseases
Bosch, F. X., Broker, T. R., Forman, D., Moscicki, A.-B., Gillison, M. L., Doorbar, J., Stern, P. L., Stanley, M., Arbyn, M., Poljak, M., et al. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.10.003 · Cited by 328
Self-citationChanging global policy to deliver safe, equitable and affordable care for women's cancers
Ginsburg, O., Badwe, R., Boyle, P., Derricks, G., Dare, A., Evans, T., Eniu, A., Jimenez, J., Kutluk, T., Lopes, G., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31393-9 · Cited by 102
Canfell, K., Kim, J. J., Kulasingam, S., Berkhof, J., Barnabas, R., Bogaards, J. A., Campos, N., Jennett, C., Sharma, M., Simms, K. T., et al. (2019) · Papillomavirus Research · doi:10.1016/j.pvr.2019.100184 · Cited by 68
Self-citation
Metadata
- Authors
- Canfell, K., Chesson, H., Kulasingam, S. L., Berkhof, J., Diaz, M., & Kim, J. J.
- Venue
- Vaccine
- Publisher
- Elsevier BV
- Published
- 2012-11
- Volume
- 30
- Pages
- F157-F167
- ISSN
- 0264-410X (ISSN-L)
- OpenAlex
- W2120440924
- Cited by
- 112
- References
- 5
- FWCI
- 9.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Modeling Preventative Strategies against Human Papillomavirus-Related Disease in Developed Countries. https://app.cochat.ai/papers/10.1016/j.vaccine.2012.06.091
- The paper
- Canfell, K., Chesson, H., Kulasingam, S. L., Berkhof, J., Diaz, M., & Kim, J. J. (2012). Modeling Preventative Strategies against Human Papillomavirus-Related Disease in Developed Countries. Vaccine. https://doi.org/10.1016/j.vaccine.2012.06.091
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.